[8-K] Kindly MD, Inc. Reports Material Event

Rhea-AI Filing Summary

Kindly MD, Inc. reported that it has released its financial results for the fiscal quarter ended September 30, 2025, through a press release. The company furnished this information in a current report under Item 2.02, which covers results of operations and financial condition, and attached the press release as Exhibit 99.1. Kindly MD’s common stock trades on The Nasdaq Stock Market under the symbol NAKA, and its tradeable warrants trade on the OTC Pink Market under NAKAW. The company is identified as an emerging growth company, and the report is signed by its Chief Executive Officer, David Bailey.

false 0001946573 0001946573 2025-11-19 2025-11-19 0001946573 NAKA:CommonStockParValue0.001Member 2025-11-19 2025-11-19 0001946573 NAKA:TradeableWarrantsToPurchaseSharesOfCommonStockParValue0.001PerShareMember 2025-11-19 2025-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 19, 2025

Kindly MD, Inc.

(Exact name of registrant as specified in its charter)

001-42103		84-3829824
(Commission File Number)		(IRS Employer Identification Number)
5097 South 900 East, Suite 100, Salt Lake City, UT Utah		84117
(Address of Principal Executive Offices)		(Zip Code)

(385) 388-8220

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.001		NAKA		The Nasdaq Stock Market LLC
Tradeable Warrants to purchase shares of Common Stock, par value $0.001 per share		NAKAW		OTC Pink Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 19, 2025, Kindly MD, Inc., a Utah corporation (the “Company”) issued a press release, announcing the Company’s financial results for the fiscal quarter ended September 30, 2025.

The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 18. The information contained in this Item 2.02 and Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibit
99.1		Press Release of Kindly MD, Inc.
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunder duly authorized.

	KINDLY MD, INC.
Dated: November 19, 2025	By:	/s/ David Bailey
		David Bailey
		Chief Executive Officer

3

FAQ

What did Kindly MD (NAKA) announce in this 8-K?

Kindly MD, Inc. announced that it has released its financial results for the fiscal quarter ended September 30, 2025, through a press release furnished with the report as Exhibit 99.1.

Which period do the Kindly MD (NAKA) results in this report cover?

The results discussed by Kindly MD, Inc. in this report cover its financial performance for the fiscal quarter ended September 30, 2025.

How did Kindly MD (NAKA) provide its Q3 2025 financial results to investors?

Kindly MD, Inc. provided its Q3 2025 financial results through a press release, which is included with the report as Exhibit 99.1 and furnished under Item 2.02.

On which markets are Kindly MD (NAKA) securities traded?

Kindly MD, Inc.’s common stock trades on The Nasdaq Stock Market under the symbol NAKA, and its tradeable warrants to purchase common stock trade on the OTC Pink Market under the symbol NAKAW.

Who signed the Kindly MD (NAKA) 8-K regarding Q3 2025 results?

The report was signed on behalf of Kindly MD, Inc. by David Bailey, who serves as the company’s Chief Executive Officer.

Is Kindly MD (NAKA) identified as an emerging growth company?

Yes. The report indicates that Kindly MD, Inc. is considered an emerging growth company under the applicable securities regulations.